Oncology Xagena
The likelihood of a patient responding to immune checkpoint blockade may depend on B cells in the tumor, located within specialized immune-cell clusters known as tertiary lymphoid structures ( TLS ), ...
Results from the phase III IMbrave150 study evaluating Atezolizumab ( Tecentriq ) in combination with Bevacizumab ( Avastin ) were presented. The data have shown statistically significant and clinic ...
Sorafenib ( Nexavar ) is approved as first-line therapy for patients with advanced hepatocellular carcinoma ( HCC ), but there is still an unmet need to prolong survival and improve tolerability. A ...
The triplet combination of the BRAF inhibitor, Encorafenib ( Braftovi ), MEK inhibitor, Binimetinib ( Mektovi ), and EGFR inhibitor, Cetuximab ( Erbitux ), not only has significantly improved overall ...
Over 60% of patients with stage IV melanoma may develop brain metastases, resulting in a significantly increased morbidity and poor overall prognosis. Clinical data for melanoma brain metastases ( M ...
The first-line treatment with Pembrolizumab ( Keytruda ), an anti-PD-1 therapy, in combination with chemotherapy has demonstrated improvements in overall survival ( OS ), progression-free survival ( P ...
Hyperprogressive disease ( HPD ) is a paradoxical boost in tumour growth described in a subset of cancer patients treated with immune checkpoint inhibitors ( ICIs ). Researchers retrospectively col ...
Positive results from the phase 3 PAOLA-1 trial in women with advanced ovarian cancer. were announced. The trial, in the first-line maintenance setting, compared Olaparib ( Lynparza ) added to stand ...
Detailed results from the phase III CASPIAN trial were presented at IASLC 2019 World Conference on Lung Cancer hosted by the International Association for the Study of Lung Cancer in Barcelona, Spain. ...
Neoadjuvant, or pre-surgical, treatment with Nivolumab ( Opdivo ) plus Ipilimumab ( Yervoy ) resulted in an overall major pathologic response ( MPR ) rate of 33% of treated patients with early-stage, ...
Some patients with metastatic prostate cancer respond to a combination of immune checkpoint inhibitors after hormonal therapy and chemotherapy have failed, according to early results from a clinical t ...
The FDA ( Food and Drug Administration ) has approved Keytruda ( Pembrolizumab ), an anti-PD-1 therapy, in combination with Inlyta ( Axitinib ), a tyrosine kinase inhibitor, for the first-line treatme ...
Non-clear cell renal cell carcinoma ( NccRCC ) and clear cell renal cell carcinoma with sarcomatoid differentiation ( sccRCC ) have historically been underrepresented in clinical trials. Even with ta ...
Several clinical trials studying mutIDH inhibitors in glioma and other solid tumors are ongoing or in planning stages and involve both pan and specific inhibitors. In 2015, the first phase 1 data o ...
In KEYNOTE-189, Pembrolizumab ( Keytruda ) plus Pemetrexed ( Alimta ) and Platinum provided superior overall survival ( OS ) ( hazard ratio, HR 0.49, P less than 0.00001 ) and progression-free surviva ...
